Correction to Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsDermatology and Skin Diseases · Asthma and respiratory diseases · Allergic Rhinitis and Sensitization
Kosloski MP, Guttman‐Yassky E, Cork MJ, et al. Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials. Clin Transl Sci. 2024; 17: e13874. doi:10.1111/cts.13874
In Figure 2 panels a and b, the Y‐axis label should be mg/L, not mg/mL.
In Figure 3 panels a and b, the Y‐axis label should be ng/mL, not mg/L.
Concentration time proles of total IL‐33 in East Asian and non‐East Asian patients during the study period in the (A) dose‐ranging study and (B) proof‐of‐concept study.
In Figure S4 (all panels), the Y‐axis label should be ng/mL, not mg/L.
We apologize for this error.